Outlook Therapeutics Rallies 50% and Breaches 100-Day MA After FDA Appeal Win
OTLK•Outlook Therapeutics shares jumped over 50% premarket after FDA granted its Formal Dispute Resolution appeal for Lytenava, concluding sufficient evidence for wet AMD effectiveness. The company plans to resubmit its BLA in June 2026, expecting a Class 1 review with a regulatory decision within 60 days.
1. FDA FDR Appeal Victory
Outlook Therapeutics received an FDA win after a Formal Dispute Resolution appeal on Lytenava, with regulators concluding the company provided sufficient evidence for effectiveness in neovascular age-related macular degeneration. The treatment has prior approvals in the European Union and United Kingdom.
2. BLA Resubmission Timeline
The company plans to resubmit its Biologics License Application in June 2026, expecting a Class 1 review designation that could yield a regulatory decision within 60 days post-resubmission. This timeline offers a clear path to potential U.S. approval if FDA requirements continue to be met.
3. Stock Reaction and Technical Breakthrough
Shares of Outlook Therapeutics surged over 50% in premarket trading and broke above the 100-day moving average for the first time in nearly five months, reflecting renewed investor confidence. Despite a year-to-date decline of around 83%, this technical breakout may signal a shift in market sentiment toward the stock.
